期刊
GYNECOLOGIC ONCOLOGY
卷 122, 期 3, 页码 580-584出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2011.05.008
关键词
Granulosa cell tumor; Mutation; FOXL2; MALD1-TOF-MS
资金
- Legacy Heritage Clinical Research Initiative of the Israel Science Foundation [1716/08]
- Israel Cancer Research Fund (ICRF)
Objective. To develop a rapid, sensitive and reliable method to detect FOXL2 C402G mutation in granulosa cell tumor (GCT) and to investigate the prevalence of FOXL2 mutation in granulose cell tumors among Israeli patients. Methods. We designed and optimized a matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) genotyping assay to detect FOXL2 C4020 mutation in DNA isolated from formalin-fixed paraffin-embedded tissue samples. We examined 20 tumor samples obtained from Israeli patients diagnosed with granulose cell tumor. Results. Eighteen out of 20 samples were found to harbor FOXI.2 C4020 mutation. Pathological review of the two tumors harboring wild type FOXL2 (C402) concluded that they were adenocarcinomas and has been misclassified at initial diagnosis. We found that the prevalence of FOXL2 mutations among Israeli patients with GCT (100%) is similar to previous reports. Conclusions. Our results indicate that the FOXL2 mutations can be reliably detected by MALDI-TOF-MS genotyping. MALDI-TOF-MS genotyping is a simple, robust and highly sensitive method to detect FOXL2 C4020 mutation. Our results confirm previous studies reporting over 95% prevalence of FOXL2 mutation in GCE Furthermore, we suggest that testing for the presence of the FOXL2 C4020 mutation may improve diagnostic accuracy. (C) 2011 Elsevier Inc. All rights reserved,
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据